Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd successfully conducted a General Meeting with all resolutions passed by a poll, reflecting strong shareholder support. The company, known for its development of a broad-spectrum oral cannabinoid drug therapy for paediatric neurological disorders, has reported significant clinical trial results for conditions including Autism Spectrum Disorder and PANDAS/PANS. These developments could be of interest to investors monitoring advancements in biopharmaceutical treatments and considering the impact on Neurotech’s stock.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
